Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer

Molecular Cancer Research

Volumn 13, Issue 4, 2015, Pages 620-635

  Bon, Hélène ^a   Wadhwa, Karan ^a   Schreiner, Alexander ^a   Osborne, Michelle ^a   Carroll, Thomas ^a,i   Ramos Montoya, Antonio ^a,j   Ross Adams, Helen ^a   Visser, Matthieu ^b   Hoffmann, Ralf ^b   Ahmed, Ahmed Ashour ^c,d   Neal, David E ^e,f   Mills, Ian G ^a,g,h  

^a UK Cambridge Research Institute (CRI)   (United Kingdom)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ARN 3236; AUTOANTIBODY; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FORSKOLIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SALT INDUCIBLE KINASE 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CREB1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SALT-INDUCIBLE KINASE-2, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FRACTIONATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LNCAP CELL LINE; LUCIFERASE ASSAY; MALE; MITOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; BLOOD; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; AUTOANTIBODIES; CELL CYCLE; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOSIS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84928016334     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0182-T     Document Type: Article

References (50)

1. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/.
2. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184:162-7.
3. Kirby M, Hirst C, Crawford E. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65: 1180-92.
4. Kahn B, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
5. Muraoka M, Fukushima A, Viengchareun S, Lombés M, Kishi F, Miyauchi A, et al. Involvement of SIK2/TORC2 signaling cascade in the regulation of insulin-induced PGC-1 and UCP-1 gene expression in brown adipocytes. Am J Physiol Endocrinol Metab 2009;296: E1430-9.
6. Koo S-H, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437:1109-11.
7. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 2007;449:366-9.
8. Wang B, Goode J, Best J, Meltzer J, Schilman PE, Chen J, et al. The insulinregulated CREB coactivator TORC promotes stress resistance in drosophila. Cell Metab 2008;7:434-44.
9. Ryu D, Oh KJ, Jo HY, Hedrick S, Kim YN, Hwang YJ, et al. TORC2 regulates hepatic insulin signaling via amammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 2009;9:240-51.
10. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, et al. The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell 2004;119:61-74.
11. Sasaki T, Takemori H, Yagita Y, Terasaki Y, Uebi T, Horike N, et al. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron 2011;69:106-19.
12. Lonze B, Ginty D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002;35:605-23.
13. Conkright MD, CanettieriG, Screaton R,Guzman E,Miraglia L, Hogenesch JB, et al. TORCs. Mol Cell 2003;12:413-23.
14. Katoh Y, Takemori H, Lin XZ, Tamura M, Muraoka M, Satoh T, et al. Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling cascade. FEBS J 2006;273:2730-48.
15. Katoh M, Katoh M. Identification and characterization of human KIAA1391 and mouse Kiaa1391 genes encoding novel RhoGAP family proteins with RA domain and ANXL repeats. Int J Oncol 2003;23: 1471-6.
16. ImielinskiM, Berger AH, Hammerman PS,Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20.
17. Wehr MC, Holder MV, Gailite I, Saunders RE, Maile TM, Ciirdaeva E, et al. Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila. Nat Cell Biol 2013;15:61-71.
18. Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Zaborski M, et al. Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51:881-91.
19. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010;18:109-21.
20. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 2003;7:1-88.
21. Ghevaria N, Visser M, Hoffmann R. Quality control for a large-scale study using protein arrays and protein beads to measure immune response in serum and plasma. Proteomics 2012;12:2802-7.
22. Alfredi A, Zhang S, Mao W, Wang Y, Takemori H, Lu Z, et al. Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts. In: Proceedings of the 105th AnnualMeeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr: 749.
23. Wersto R, Chrest FJ, Leary JF, Morris C, Stetler-StevensonMA, Gabrielson E. Doublet discrimination in DNA cell-cycle analysis. Cytometry 2001; 46:296-306.
24. Dunning M, Smith ML, Ritchie ME, Tavaré S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007;23: 2183-4.
25. Zweig M, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39: 561-77.
26. Horike N, Takemori H, Katoh Y, Doi J, Min L, Asano T, et al. Adiposespecific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2. J Biol Chem 2003;278:18440-7.
27. Wiese C, Zheng Y. Microtubule nucleation: gamma-tubulin and beyond. J Cell Sci 2006;119(Pt 20):4143-53.
28. Souza N, Dohadwalla A, Reden J. Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 1983;3: 201-19.
29. Ravnskjaer K, Kester H, Liu Y, Zhang X, Lee D, Yates JR III, et al. Cooperative interactions between CBPandTORC2 confer selectivity toCREB target gene expression. EMBO J 2007;26:2880-9.
30. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 2005;102:4459-64.
31. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009;15:752-7.
32. Nunes FD, de Almeida FC, Tucci R, de Sousa SC. Homeobox genes: a molecular link between development and cancer. Pesqui Odontol Bras 2003;17:94-8.
33. Muta T. IkappaB-zeta: an inducible regulator of nuclear factor-kappaB. Vitam Horm 2006;74:301-16.
34. Hee SW, Tsai SH, Chang YC, Chang CJ, Yu IS, Lee PC, et al. The role of nocturnin in early adipogenesis and modulation of systemic insulin resistance in human. Obesity 2012;20:1558-65.
35. Segatto O, Anastasi S, Alema S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 2011;124 (Pt 11):1785-93.
36. den Hertog J, Blanchetot C, Buist A, Overvoorde J, van der Sar A, Tertoolen LG. Receptor protein-tyrosine phosphatase signalling in development. Int J Dev Biol 1999;43:723-33.
37. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 2007;8:R3.
38. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res 2009;37(Web Server issue):W317-22.
39. Cancer Genome Atlas Research NetworkWeinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
40. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
41. Bright NJ, Thornton C, Carling D. The regulation and function of mammalian AMPK-related kinases. Acta Physiol 2009;196:15-26.
42. Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein kinase: new regulation, new roles? Biochem J 2012;445:11-27.
43. Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 2008;8:723-31.
44. Mohammed H, D'Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep 2013;3:342-9.
45. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, et al. cAMPresponsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 2007;26:5070-7.
46. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275:10761-6.
47. Yune TY, Park HG, Lee JY, Oh TH. Estrogen-induced Bcl-2 expression after spinal cord injury is mediated through phosphoinositide-3-kinase/Aktdependent CREB activation. J Neurotrauma 2008;25:1121-31.
48. Wei G, Chen YB, Chen DF, Lai XP, Liu DH, Deng RD, et al. beta-Asarone inhibits neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in an in vitro model and AbetaPP/PS1 mice. J Alzheimers Dis 2013;33: 863-80.
49. Rokhlin OW,Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, et al. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther 2007;6:732-42.
50. Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36:65-77.